Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas

Journal of Clinical Neuroscience

Volumn 16, Issue 9, 2009, Pages 1119-1130

  Wong, Michael L H ^a,b   Prawira, Amy ^a   Kaye, Andrew H ^a,b   Hovens, Christopher M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Angiogenesis; Clinical trials; Glioma

Indexed keywords

2 METHOXYESTRADIOL; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CILENGITIDE; DEFOROLIMUS; ENZASTAURIN; EVEROLIMUS; GROWTH FACTOR; IMMUNOMODULATING AGENT; IRINOTECAN; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; PRINOMASTAT; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTHRALGIA; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FATIGUE; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY CANCER; LIVER TOXICITY; LUNG CANCER; MICROVASCULATURE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RECURRENT CANCER; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THRUSH; TREATMENT OUTCOME; TUMOR BLOOD FLOW; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN NEOPLASMS; GLIOMA; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REGIONAL BLOOD FLOW;

EID: 67650713544     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.02.009     Document Type: Review

References (277)

1. Risau W., and Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 11 (1995) 73-91
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
3. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
4. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
5. Yancopoulos G.D., Davis S., Gale N.W., et al. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
6. Folkman J., and Shing Y. Angiogenesis, J Biol Chem 267 (1992) 10931-10934
7. Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
8. Tonnesen M.G., Feng X., and Clark R.A. Angiogenesis in wound healing. J Investig Dermatol Symp Proc 5 (2000) 40-46
9. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
10. Algire G.H., and Chalkley H.W. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst USA 6 (1945) 73-85
11. Goldman E. The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet 2 (1907) 1236-1240
12. Ide A.G., Baker N.H., and Warren S.L. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Radiol 42 (1939) 891-899
13. Folkman J., Cole P., and Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164 (1966) 491-502
14. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
15. Rijken P.F., Bernsen H.J., Peters J.P., et al. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 48 (2000) 571-582
16. Gimbrone Jr. M.A., Cotran R.S., Leapman S.B., et al. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 52 (1974) 413-427
17. Gimbrone Jr. M.A., Leapman S.B., Cotran R.S., et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136 (1972) 261-276
18. Knighton D., Ausprunk D., Tapper D., et al. Avascular and vascular phases of tumour growth in the chick embryo. Br J Cancer 35 (1977) 347-356
19. Lien W.M., and Ackerman N.B. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery 68 (1970) 334-340
20. Thompson W.D., Shiach K.J., Fraser R.A., et al. Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth. J Pathol 151 (1987) 323-332
21. Ehrmann R.L., and Knoth M. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J Natl Cancer Inst 41 (1968) 1329-1341
22. Greenblatt M., and Shubi P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J Natl Cancer Inst 41 (1968) 111-124
23. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
24. Gullino P.M. Angiogenesis and oncogenesis. J Natl Cancer Inst 61 (1978) 639-643
25. Dameron K.M., Volpert O.V., Tainsky M.A., et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 (1994) 1582-1584
26. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
27. Rak J., Filmus J., Finkenzeller G., et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14 (1995) 263-277
28. Volpert O.V., Dameron K.M., and Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14 (1997) 1495-1502
29. Bello L., Giussani C., Carrabba G., et al. Angiogenesis and invasion in gliomas. Cancer Treat Res 117 (2004) 263-284
30. Cheng S.Y., Huang H.J., Nagane M., et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93 (1996) 8502-8507
31. Zagzag D. Angiogenic growth factors in neural embryogenesis and neoplasia. Am J Pathol 146 (1995) 293-309
32. Brem S., Cotran R., and Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48 (1972) 347-356
33. Del Maestro R.F., Megyesi J.F., and Farrell C.L. Mechanisms of tumor-associated edema: a review. Can J Neurol Sci 17 (1990) 177-183
34. Vaquero J., Zurita M., Morales C., et al. Expression of vascular permeability factor in glioblastoma specimens: correlation with tumor vascular endothelial surface and peritumoral edema. J Neurooncol 49 (2000) 49-55
35. Zagzag D., Brem S., and Robert F. Neovascularization and tumor growth in the rabbit brain. A model for experimental studies of angiogenesis and the blood-brain barrier. Am J Pathol 131 (1988) 361-372
36. Zagzag D., Goldenberg M., and Brem S. Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model. AJR Am J Roentgenol 153 (1989) 141-146
37. Cheng S.Y., Nagane M., Huang H.S., et al. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 94 (1997) 12081-12087
38. Liwnicz B.H., Wu S.Z., and Tew Jr. J.M. The relationship between the capillary structure and hemorrhage in gliomas. J Neurosurg 66 (1987) 536-541
39. Cha S., Johnson G., Wadghiri Y.Z., et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 49 (2003) 848-855
40. Earnest F.t., Kelly P.J., Scheithauer B.W., et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166 (1988) 823-827
41. Tynninen O., Aronen H.J., Ruhala M., et al. MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 34 (1999) 427-434
42. Abdulrauf S.I., Edvardsen K., Ho K.L., et al. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 88 (1998) 513-520
43. Burger P.C., Vogel F.S., Green S.B., et al. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56 (1985) 1106-1111
44. Daumas-Duport C., Scheithauer B., O'Fallon J., et al. Grading of astrocytomas. A simple and reproducible method. Cancer 62 (1988) 2152-2165
45. Kleihues P., Burger P.C., Collins V.P., et al. Glioblastoma. In: Kleihues P., and Cavenee W.K. (Eds). Pathology and Genetics of Tumours of the Nervous System (2000), IARC Press, Lyon 29-39
46. Straume O., Chappuis P.O., Salvesen H.B., et al. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res 62 (2002) 6808-6811
47. Brem S. The role of vascular proliferation in the growth of brain tumors. Clin Neurosurg 23 (1976) 440-453
48. Abe T., Okamura K., Ono M., et al. Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis. J Clin Invest 92 (1993) 54-61
49. Suddith R.L., Kelly P.J., Hutchison H.T., et al. In vitro demonstration of an endothelial proliferative factor produced by neural cell lines. Science 190 (1975) 682-684
50. Dvorak H.F. Angiogenesis: update 2005. J Thromb Haemost 3 (2005) 1835-1842
51. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
52. Plate K.H., Breier G., Weich H.A., et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
53. Roberts W.G., and Palade G.E. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57 (1997) 765-772
54. Shweiki D., Itin A., Soffer D., et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
55. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
56. Zagzag D., Zhong H., Scalzitti J.M., et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88 (2000) 2606-2618
57. Ausprunk D.H., and Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Research 14 (1977) 53-65
58. Gladson C.L. The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 58 (1999) 1029-1040
59. Ljubimova J.Y., Fujita M., Khazenzon N.M., et al. Changes in laminin isoforms associated with brain tumor invasion and angiogenesis. Front Biosci 11 (2006) 81-88
60. Mikkelsen T., Yan P.S., Ho K.L., et al. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J Neurosurg 83 (1995) 285-290
61. Zagzag D., Friedlander D.R., Dosik J., et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 56 (1996) 182-189
62. Zagzag D., Friedlander D.R., Miller D.C., et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 55 (1995) 907-914
63. Haskell H., Natarajan M., Hecker T.P., et al. Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells. Clin Cancer Res 9 (2003) 2157-2165
64. Zagzag D., Friedlander D.R., Margolis B., et al. Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg 33 (2000) 49-55
65. Zagzag D., Shiff B., Jallo G.I., et al. Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res 62 (2002) 2660-2668
66. Folkman J. Angiogenesis: initiation and control. Ann N Y Acad Sci 401 (1982) 212-227
67. Folkman J. Tumor angiogenesis. Adv Cancer Res 43 (1985) 175-203
68. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 46 (1986) 467-473
69. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
70. Zagzag D., Amirnovin R., Greco M.A., et al. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80 (2000) 837-849
71. Zagzag D., Hooper A., Friedlander D.R., et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159 (1999) 391-400
72. Kieran M.W. Anti-angiogenic chemotherapy in central nervous system tumors. Cancer Treat Res 117 (2004) 337-349
73. Neufeld G., Cohen T., Gengrinovitch S., et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 (1999) 9-22
74. Autiero M., Luttun A., Tjwa M., et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1 (2003) 1356-1370
75. Autiero M., Waltenberger J., Communi D., et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9 (2003) 936-943
76. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
77. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 (2002) 795-803
78. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
79. Gerber H.P., Malik A.K., Solar G.P., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002) 954-958
80. Hattori K., Heissig B., Wu Y., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 8 (2002) 841-849
81. Luttun A., Tjwa M., Moons L., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8 (2002) 831-840
82. Hiratsuka S., Nakamura K., Iwai S., et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2 (2002) 289-300
83. LeCouter J., Moritz D.R., Li B., et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299 (2003) 890-893
84. Safran M., and Kaelin Jr. W.G. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 111 (2003) 779-783
85. Loeffler S., Fayard B., Weis J., et al. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 115 (2005) 202-213
86. Valter M.M., Hugel A., Huang H.J., et al. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res 59 (1999) 5608-5614
87. Sahin A., Velten M., Pietsch T., et al. Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. Int J Mol Med 15 (2005) 771-776
88. Cohen T., Nahari D., Cerem L.W., et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271 (1996) 736-741
89. Finkenzeller G., Marme D., Weich H.A., et al. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res 52 (1992) 4821-4823
90. Guo P., Hu B., Gu W., et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162 (2003) 1083-1093
91. Pertovaara L., Kaipainen A., Mustonen T., et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269 (1994) 6271-6274
92. Tsai J.C., Goldman C.K., and Gillespie G.Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 82 (1995) 864-873
93. Wang D., Huang H.J., Kazlauskas A., et al. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 59 (1999) 1464-1472
94. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 (2002) 4368-4380
95. Berkman R.A., Merrill M.J., Reinhold W.C., et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91 (1993) 153-159
96. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 (2002) 727-739
97. Rak J., Mitsuhashi Y., Bayko L., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55 (1995) 4575-4580
98. Berra E., Milanini J., Richard D.E., et al. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 60 (2000) 1171-1178
99. Gnarra J.R., Zhou S., Merrill M.J., et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93 (1996) 10589-10594
100. Na X., Wu G., Ryan C.K., et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170 (2003) 588-592
101. Pore N., Liu S., Haas-Kogan D.A., et al. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 63 (2003) 236-241
102. Wen S., Stolarov J., Myers M.P., et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98 (2001) 4622-4627
103. Doanes A.M., Hegland D.D., Sethi R., et al. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun 255 (1999) 545-548
104. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280 (2001) C1358-C1366
105. Esser S., Lampugnani M.G., Corada M., et al. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 111 (1998) 1853-1865
106. Kevil C.G., Payne D.K., Mire E., et al. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem 273 (1998) 15099-15103
107. Lal B.K., Varma S., Pappas P.J., et al. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res 62 (2001) 252-262
108. Mandriota S.J., Seghezzi G., Vassalli J.D., et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 270 (1995) 9709-9716
109. Pepper M.S., Ferrara N., Orci L., et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181 (1991) 902-906
110. Tang H., Kerins D.M., Hao Q., et al. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 273 (1998) 18268-18272
111. Senger D.R., Claffey K.P., Benes J.E., et al. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci USA 94 (1997) 13612-13617
112. Senger D.R., Ledbetter S.R., Claffey K.P., et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149 (1996) 293-305
113. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6 (2000) 389-395
114. Gerber H.P., Dixit V., and Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273 (1998) 13313-13316
115. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273 (1998) 30336-30343
116. Watanabe Y., Lee S.W., Detmar M., et al. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 14 (1997) 2025-2032
117. Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R., et al. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 420 (1997) 28-32
118. Gupta K., Kshirsagar S., Li W., et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 247 (1999) 495-504
119. Dimmeler S., and Zeiher A.M. Akt takes center stage in angiogenesis signaling. Circ Res 86 (2000) 4-5
120. Jiang B.H., Zheng J.Z., Aoki M., et al. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 97 (2000) 1749-1753
121. Fujio Y., and Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274 (1999) 16349-16354
122. Khwaja A. Akt is more than just a Bad kinase. Nature 401 (1999) 33-34
123. Morales-Ruiz M., Fulton D., Sowa G., et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res 86 (2000) 892-896
124. Mazure N.M., Chen E.Y., Laderoute K.R., et al. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90 (1997) 3322-3331
125. Dimmeler S., Fleming I., Fisslthaler B., et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 (1999) 601-605
126. Fulton D., Gratton J.P., McCabe T.J., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399 (1999) 597-601
127. Dulak J., Jozkowicz A., Dembinska-Kiec A., et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20 (2000) 659-666
128. Ziche M., Parenti A., Ledda F., et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 80 (1997) 845-852
129. Dimmeler S., Dernbach E., and Zeiher A.M. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 477 (2000) 258-262
130. Murohara T., Witzenbichler B., Spyridopoulos I., et al. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol 19 (1999) 1156-1161
131. Ziche M., Morbidelli L., Masini E., et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94 (1994) 2036-2044
132. Stratmann A., Risau W., and Plate K.H. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153 (1998) 1459-1466
133. Zadeh G., Qian B., Okhowat A., et al. Targeting the Tie2/Tek receptor in astrocytomas. Am J Pathol 164 (2004) 467-476
134. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
135. Kim I., Kim H.G., So J.N., et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ Res 86 (2000) 24-29
136. Harfouche R., Hassessian H.M., Guo Y., et al. Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 64 (2002) 135-147
137. Papapetropoulos A., Fulton D., Mahboubi K., et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275 (2000) 9102-9105
138. Kim I., Kim H.G., Moon S.O., et al. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circ Res 86 (2000) 952-959
139. Lobov I.B., Brooks P.C., and Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99 (2002) 11205-11210
140. Schmidt N.O., Westphal M., Hagel C., et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84 (1999) 10-18
141. Zagzag D., Miller D.C., Sato Y., et al. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 50 (1990) 7393-7398
142. Alavi A., Hood J.D., Frausto R., et al. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301 (2003) 94-96
143. Pardo O.E., Arcaro A., Salerno G., et al. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem 277 (2002) 12040-12046
144. Yoshiji H., Kuriyama S., Yoshii J., et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35 (2002) 834-842
145. Mandriota S.J., and Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 110 (1997) 2293-2302
146. Ausprunk D.H., and Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14 (1977) 53-65
147. Sato Y., and Rifkin D.B. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 107 (1988) 1199-1205
148. Lindahl P., Johansson B.R., Leveen P., et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277 (1997) 242-245
149. Bergers G., Song S., Meyer-Morse N., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (2003) 1287-1295
150. Sun J., Wang D.A., Jain R.K., et al. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 24 (2005) 4701-4709
151. Reinmuth N., Liu W., Jung Y.D., et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 15 (2001) 1239-1241
152. Dunn I.F., Heese O., and Black P.M. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 50 (2000) 121-137
153. Maxwell M., Naber S.P., Wolfe H.J., et al. Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression. Cancer Res 51 (1991) 1345-1351
154. Goldman C.K., Kim J., Wong W.L., et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4 (1993) 121-133
155. Feldkamp M.M., Lau N., Rak J., et al. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer 81 (1999) 118-124
156. Wu J.L., Abe T., Inoue R., et al. IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells. Neurol Res 26 (2004) 785-791
157. Yamada N., Kato M., Yamashita H., et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62 (1995) 386-392
158. Luwor R.B., Kaye A.H., and Zhu H.J. Transforming growth factor-beta (TGF-beta) and brain tumours. J Clin Neurosci 15 (2008) 845-855
159. Frater-Schroder M., Muller G., Birchmeier W., et al. Transforming growth factor-beta inhibits endothelial cell proliferation. Biochem Biophys Res Commun 137 (1986) 295-302
160. Fajardo L.F., Prionas S.D., Kwan H.H., et al. Transforming growth factor beta1 induces angiogenesis in vivo with a threshold pattern. Lab Invest 74 (1996) 600-608
161. Koochekpour S., Merzak A., and Pilkington G.J. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett 102 (1996) 209-215
162. Hjelmeland M.D., Hjelmeland A.B., Sathornsumetee S., et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3 (2004) 737-745
163. Platten M., Wick W., and Weller M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52 (2001) 401-410
164. Platten M., Wick W., Wild-Bode C., et al. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun 268 (2000) 607-611
165. Kunkel P., Muller S., Schirmacher P., et al. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro Oncol 3 (2001) 82-88
166. Abounader R., Lal B., Luddy C., et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 16 (2002) 108-110
167. Brockmann M.A., Papadimitriou A., Brandt M., et al. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 9 (2003) 4578-4585
168. Van Meir E., Ceska M., Effenberger F., et al. Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res 52 (1992) 4297-4305
169. Van Meir E., Sawamura Y., Diserens A.C., et al. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 50 (1990) 6683-6688
170. Brat D.J., Bellail A.C., and Van Meir E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7 (2005) 122-133
171. Rolhion C., Penault-Llorca F., Kemeny J.L., et al. Interleukin-6 overexpression as a marker of malignancy in human gliomas. J Neurosurg 94 (2001) 97-101
172. Hu D.E., Hori Y., and Fan T.P. Interleukin-8 stimulates angiogenesis in rats. Inflammation 17 (1993) 135-143
173. Koch A.E., Polverini P.J., Kunkel S.L., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258 (1992) 1798-1801
174. Desbaillets I., Diserens A.C., Tribolet N., et al. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 186 (1997) 1201-1212
175. Wakabayashi Y., Shono T., Isono M., et al. Dual pathways of tubular morphogenesis of vascular endothelial cells by human glioma cells: vascular endothelial growth factor/basic fibroblast growth factor and interleukin-8. Jpn J Cancer Res 86 (1995) 1189-1197
176. Desbaillets I., Diserens A.C., de Tribolet N., et al. Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene 18 (1999) 1447-1456
177. Maruno M., Kovach J.S., Kelly P.J., et al. Distribution of endogenous tumour necrosis factor alpha in gliomas. J Clin Pathol 50 (1997) 559-562
178. Roessler K., Suchanek G., Breitschopf H., et al. Detection of tumor necrosis factor-alpha protein and messenger RNA in human glial brain tumors: comparison of immunohistochemistry with in situ hybridization using molecular probes. J Neurosurg 83 (1995) 291-297
179. Chambaut-Guerin A.M., Costa S.L., Lefrancois T., et al. Effects of retinoic acid and tumor necrosis factor alpha on GL-15 glioblastoma cells. Neuroreport 11 (2000) 389-393
180. Slowik M.R., De Luca L.G., Fiers W., et al. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 143 (1993) 1724-1730
181. Ryuto M., Ono M., Izumi H., et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 271 (1996) 28220-28228
182. Yoshida S., Ono M., Shono T., et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17 (1997) 4015-4023
183. Babic A.M., Kireeva M.L., Kolesnikova T.V., et al. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 95 (1998) 6355-6360
184. Shimo T., Nakanishi T., Nishida T., et al. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem 126 (1999) 137-145
185. Leu S.J., Lam S.C., and Lau L.F. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem 277 (2002) 46248-46255
186. Xie D., Yin D., Wang H.J., et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 10 (2004) 2072-2081
187. Hirano H., Lopes M.B., Laws Jr. E.R., et al. Insulin-like growth factor-1 content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. Neuro Oncol 1 (1999) 109-119
188. Stromblad S., and Cheresh D.A. Cell adhesion and angiogenesis. Trends Cell Biol 6 (1996) 462-468
189. Bello L., Francolini M., Marthyn P., et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49 (2001) 380-389 discussion 390
190. D'Abaco G.M., and Kaye A.H. Integrins: molecular determinants of glioma invasion. J Clin Neurosci 14 (2007) 1041-1048
191. Forsyth P.A., Wong H., Laing T.D., et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79 (1999) 1828-1835
192. Rao J.S., Yamamoto M., Mohaman S., et al. Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 14 (1996) 12-18
193. Binder D.K., and Berger M.S. Proteases and the biology of glioma invasion. J Neurooncol 56 (2002) 149-158
194. Lamoreaux W.J., Fitzgerald M.E., Reiner A., et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 55 (1998) 29-42
195. Wick W., Platten M., and Weller M. Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 53 (2001) 177-185
196. Yu Q., and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14 (2000) 163-176
197. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
198. Takahashi T., Kalka C., Masuda H., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5 (1999) 434-438
199. Heissig B., Hattori K., Dias S., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109 (2002) 625-637
200. Ruzinova M.B., Schoer R.A., Gerald W., et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4 (2003) 277-289
201. De Palma M., Venneri M.A., Roca C., et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9 (2003) 789-795
202. Peters B.A., Diaz L.A., Polyak K., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11 (2005) 261-262
203. Feldman A.L., and Libutti S.K. Progress in antiangiogenic gene therapy of cancer. Cancer 89 (2000) 1181-1194
204. Bauvois B., Dumont J., Mathiot C., et al. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 16 (2002) 791-798
205. Izawa J.I., Sweeney P., Perrotte P., et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8 (2002) 1258-1270
206. Ozawa S., Shinohara H., Kanayama H.O., et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 3 (2001) 154-164
207. Slaton J.W., Perrotte P., Inoue K., et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5 (1999) 2726-2734
208. Marler JJ, Rubin JB, Trede NS, et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 2002;109:E37.
209. Jonasch E., and Haluska F.G. Interferon in oncological practice. review of interferon biology, clinical applications, and toxicities. Oncologist 6 (2001) 34-55
210. Volpert O.V., Fong T., Koch A.E., et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 188 (1998) 1039-1046
211. Duda D.G., Sunamura M., Lozonschi L., et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 60 (2000) 1111-1116
212. Oshikawa K., Rakhmilevich A.L., Shi F., et al. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer. Hum Gene Ther 12 (2001) 149-160
213. Huang S., Ullrich S.E., and Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 19 (1999) 697-703
214. Gomez D.E., Alonso D.F., Yoshiji H., et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
215. Fernandez H.A., Kallenbach K., Seghezzi G., et al. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. J Surg Res 82 (1999) 156-162
216. Murphy A.N., Unsworth E.J., and Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157 (1993) 351-358
217. Spurbeck W.W., Ng C.Y., Strom T.S., et al. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 100 (2002) 3361-3368
218. Hajitou A., Grignet C., Devy L., et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 16 (2002) 1802-1804
219. Wajih N., and Sane D.C. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood 101 (2003) 1857-1863
220. Lucas R., Holmgren L., Garcia I., et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92 (1998) 4730-4741
221. Moser T.L., Kenan D.J., Ashley T.A., et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 98 (2001) 6656-6661
222. Moser T.L., Stack M.S., Asplin I., et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96 (1999) 2811-2816
223. Kim Y.M., Hwang S., Kim Y.M., et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277 (2002) 27872-27879
224. Urbich C., Reissner A., Chavakis E., et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J 16 (2002) 706-708
225. Rehn M., Veikkola T., Kukk-Valdre E., et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 98 (2001) 1024-1029
226. Hohenester E., Sasaki T., Olsen B.R., et al. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 17 (1998) 1656-1664
227. Kim Y.M., Jang J.W., Lee O.H., et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60 (2000) 5410-5413
228. Dhanabal M., Ramchandran R., Waterman M.J., et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 274 (1999) 11721-11726
229. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 6 (2007) 273-286
230. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722-4729
231. Pope W.B., Lai A., Nghiemphu P., et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66 (2006) 1258-1260
232. Friedland D.M., Ali S.A., Ahmad A., et al. Bevacizumab plus irinotecan therapy in relapsed, heavily pre-treated malignant glioma: A case series. J Clin Oncol (Meeting Abstracts) 25 18 Suppl. (2007) 12500
233. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. Procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 (2000) 588-593
234. ®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407 (2005) 597-612
235. Nabors L.B., Rosenfeld M., Chamberlain M., et al. A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401). J Clin Oncol (Meeting Abstracts) 25 18 Suppl. (2007) 2058
236. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
237. Batchelor T., Sorensen A.G., Ancukiewicz M., et al. A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (Meeting Abstracts) 25 18 Suppl. (2007) 2001
238. Bold G., Altmann K.H., Frei J., et al. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem 43 (2000) 2310-2323
239. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
240. Sathornsumetee S., Rich J.N., Vredenburgh J.J., et al. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts) 25 18 Suppl. (2007) 2027
241. Traxler P., Allegrini P.R., Brandt R., et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64 (2004) 4931-4941
242. Reardon D., Cloughesy T., Conrad C., et al. A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. J Clin Oncol (Meeting Abstracts) 23 16 Suppl. (2005) 3063
243. Wong M.L., Kaye A.H., and Hovens C.M. Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14 (2007) 301-308
244. Chang S.M., Wen P., Cloughesy T., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23 (2005) 357-361
245. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23 (2005) 5294-5304
246. Nguyen TD, Lassman AB, Lis E, et al. A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts), 2006;24:1507.
247. Phuphanich S, Supko J, Carson KA, et al. Phase I trial of bortezomib in adults with recurrent malignant glioma. J Clin Oncol (Meeting Abstracts), 2006;24:1567.
248. Dicker A., Werner-Wasik M., Machtay M., et al. A phase I trial using the proteasome inhibitor bortezomib and concurrent temazolomide and radiotherapy for high grade gliomas. J Clin Oncol (Meeting Abstracts) 25 18 Suppl. (2007) 2061
249. Graff J.R., McNulty A.M., Hanna K.R., et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65 (2005) 7462-7469
250. Teicher B.A., Alvarez E., Menon K., et al. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother Pharmacol 49 (2002) 69-77
251. Fine H.A., Kim L., Royce C., et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol (Meeting Abstracts) 23 16 Suppl. (2005) 1504
252. Butowski N.A., Lamborn K., Chang S., et al. Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma. J Clin Oncol (Meeting Abstracts) 25 18 Suppl. (2007) 12511
253. Gupta D., Treon S.P., Shima Y., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15 (2001) 1950-1961
254. Tamilarasan K.P., Kolluru G.K., Rajaram M., et al. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol 7 (2006) 17
255. Fine H.A., Figg W.D., Jaeckle K., et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18 (2000) 708-715
256. Fine H.A., Wen P.Y., Maher E.A., et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21 (2003) 2299-2304
257. Puduvalli V.K., Giglio P., Groves M.D., et al. Phase II trial of thalidomide in combination with irinotecan in adults with recurrent glioblastoma multiforme. J Clin Oncol (Meeting Abstracts) 23 16 Suppl. (2005) 1524
258. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
259. Fine H.A., Kim L., Albert P.S., et al. A Phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 13 (2007) 7101-7106
260. Ma L., del Soldato P., and Wallace J.L. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci USA 99 (2002) 13243-13247
261. Pannullo S.C., Burton J., Serventi J., et al. Phase I/II trial of twice-daily temozolomide and celecoxib for treatment of relapsed malignant glioma: Final data. J Clin Oncol (Meeting Abstracts) 24 18 Suppl. (2006) 1519
262. Rosenblum M.G., Yung W.K., Kelleher P.J., et al. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2′, 5′-oligoadenylate synthetase and protein kinase activity. J Interferon Res 10 (1990) 141-151
263. Kuroki M., Tanaka R., Suzuki Y., et al. Antitumor effect of recombinant murine interferon-beta against mouse malignant glioma. J Interferon Res 7 (1987) 301-311
264. Hong Y.K., Chung D.S., Joe Y.A., et al. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin Cancer Res 6 (2000) 3354-3360
265. Singh R.K., Gutman M., Bucana C.D., et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92 (1995) 4562-4566
266. Groves M.D., Puduvalli V., Gilbert M.R., et al. A phase II study of temozolomide plus pegylated interferon alfa-2b for recurrent anaplastic glioma and glioblastoma multiforme. J Clin Oncol (Meeting Abstracts) 23 16 Suppl. (2005) 1519
267. Lawson D.H., Phuphanich S., McKenzie E., et al. Phase I analysis of systemic interferon alpha utilized with gliadel in adults with recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts) 24 18 Suppl. (2006) 11508
268. Loges S., Butzal M., Otten J., et al. Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun 357 (2007) 1016-1020
269. Yamada S., Bu X.Y., Khankaldyyan V., et al. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59 (2006) 1304-1312 discussion 1312
270. Reardon D., Fink K., Nabors B., et al. Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009. J Clin Oncol (Meeting Abstracts) 25 18 Suppl. (2007) 2002
271. Stupp R., Goldbrunner R., Neyns B., et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol (Meeting Abstracts) 25 18 Suppl. (2007) 2000
272. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
273. Scatena R. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin Investig Drugs 9 (2000) 2159-2165
274. Levin V., Phuphanich S., Glantz M., et al. Randomized phase II study of temozolomide (TMZ) with and without the matrix metalloprotease (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy. Proc Am Soc Clin Oncol 21 (2002) abstr 100
275. Lakhani N.J., Sarkar M.A., Venitz J., et al. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23 (2003) 165-172
276. Kirkpatrick J., Desjardins A., Quinn J., et al. Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme. J Clin Oncol (Meeting Abstracts) 25 18 Suppl. (2007) 2065
277. Gasparini G., Longo R., Fanelli M., et al. Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions. J Clin Oncol 23 (2005) 1295-1311